MENUMENU
  • HOME
  • ABOUT US
  • IBS
  • ADVOCACY
  • RESEARCH
  • IBS STUDIES
  • RESOURCES
  • IBS & CHILDREN
  • FAMILY & FRIENDS
  • LINKS
  • CONTACT US
MENUMENU
  • HOME
  • ABOUT US
  • IBS
  • ADVOCACY
  • RESEARCH
  • IBS STUDIES
  • RESOURCES
  • IBS & CHILDREN
  • FAMILY & FRIENDS
  • LINKS
  • CONTACT US

In January 2018, plecanatide, also known by the brand name Trulance, and previously available in the United States for use in chronic idiopathic constipation, was approved by the U.S. Food and Drug Administration (FDA) for treatment of irritable bowel syndrome with constipation (IBS-C).

See this link.

https://www.healio.com/gastroenterology/irritable-bowel-syndrome/news/online/%7B0aa46942-f0d1-4b90-a703-335e5878dec4%7D/fda-approves-trulance-for-ibs-c

Updated May 2018

  • Previous
  • Next

IBS Impact is a grassroots group effort of people with IBS and our supporters who volunteer our own time and resources. We are not a business or a charity. If you wish to support the IBS cause, we encourage you to donate to IBS organizations or research centers in your country. Many are linked on our Research and Links pages.

News

  • Tegaserod (Zelnorm) for IBS-C Removed From U.S. Market for Business Reasons
  • April is Irritable Bowel Syndrome (IBS) Awareness Month 2022
  • Veterans with IBS and Functional Gastrointestinal Disorders, 2021
  • Online Survey: IFFGD and WebMD IBS Experiences, October 2021
  • Online Survey: IFFGD Long COVID and Gastrointestinal Disorders 2021
  • IFFGD Seeks Participants for New Focus Group on Inequalities and Disparities in Healthcare, June 2021
  • April is IBS Awareness Month 2021
  • American College of Gastroenterology Publishes 2020 Clinical Guidelines for IBS Management-December 2020
  • IFFGD 2020 IBS Patients’ Illness Experience and Unmet Needs Online Survey Open For Response
  • U.S. FDA Approves Tenapanor (Ibsrela) for Adults with IBS-C, September 2019
  • U.S. FDA Approves IB-Stim, First Medical Device for IBS Pain in Adolescents with IBS, June 2019.
  • New Canadian Association of Gastroenterology Clinical Practice Guidelines for the Management of IBS– April 2019.
  • U.S. FDA Approves Return of Tegaserod (Zelnorm) to U.S. Market for Some Women with IBS-C, April 2019
  • Lupin Pharmaceuticals, Canada Announces Approval of Rifaximin (Zaxine) for IBS-D, December 2018
  • International Foundation for Functional Gastrointestinal Disorders (IFFGD) Seeking Volunteers for New Patient Panel

Social Media

Facebook: IBS Impact

Twitter: @ibsimpact

Blog: ibsimpact.wordpress.com

Please have your symptoms diagnosed by a medical practitioner or doctor. It is important to remember that you cannot self diagnose IBS and there are many serious conditions that can mimic some IBS symptoms. The leading cause of misdiagnosis is self-diagnosis.

© Copyright 2010-2023 by IBS Impact. All rights reserved to original content.